glp-1 constipation and diarrhea Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus GLP-1 Constipation: Miralax vs Metamucil
Description
[152] Coverage for people with obesity and at least one comorbidity like (elevated LDL-cholesterol, high blood pressure and/or MASLD), will be implemented as early as 1 April 2026
Avoid direct sunlight and extreme temps
NICE guidance (NG28) does not differentiate between agents based on anti-inflammatory properties
While the report did not delve into why patients quit, it does offer a sobering view of the real-world experiences of people taking the drugs
Notably, the MREgger regression results indicated no significant horizontal pleiotropy
The microdose path is a differentiator for side-effect-sensitive patients
